**Scilex Holding Co Changes Record Date for Dividend Payment****

**

Scilex Holding Company (OTCMKTS: SCLX) made an important announcement on December 30, 2024, through a press release stating that its Board of Directors approved a change to the previously announced record date. The company disclosed that the record date for its dividend of Series 1 Mandatory Exchangeable Preferred Stock will now be January 28, 2025, as opposed to the earlier announced date of November 7, 2024.

The dividend, targeted at the company’s stockholders and certain securityholders, will be subject to subsequent resolutions of the Board to determine the payment date within 60 days following the record date, not later than March 29, 2025. The payment will be proportionally distributed among the Record Holders based on previous announcements by the company.

The Board reserves the right to modify the Record Date if needed before the actual dividend payment, with any changes to be reported through a Current Report on Form 8-K. Payment of the dividend hinges on the Board not rescinding it before the Payment Date, especially due to significant alterations in the solvency or surplus analysis presented to the Board.

This disclosure falls under the Regulation FD (Fair Disclosure) and is being furnished for informational purposes, not filed for specific requirements under the Securities Act. The company highlights that this information should not be mistaken as incorporated by reference in future filings under the Securities Act, except by explicit reference in such filings to this report.

Forward-looking statements regarding the declaration and payment of dividends have been acknowledged by the company, with risks and uncertainties inherent in such projections. Management’s current beliefs, market conditions, and expectations underpin these statements, emphasizing that the future declaration of dividends is not guaranteed and may be rescinded based on certain conditions.

The company has also included an interactive data file in iXBRL format along with the Form 8-K filing.

For more information, readers can refer to the press release attached as Exhibit 99.1 to the Current Report.

**About Scilex Holding Company:**
Scilex Holding Company is an innovative firm focusing on non-opioid pain management products for acute and chronic pain. It is oriented towards acquiring, developing, and commercializing therapies, aiming to enhance patient outcomes while targeting areas with substantial market opportunities and unmet needs.

**About Semnur Pharmaceuticals, Inc.:**
Semnur Pharmaceuticals, Inc. is a clinical-late stage specialty pharmaceutical company concentrating on novel non-opioid pain therapies, particularly SEMDEXA™ for patients with chronic radicular pain/sciatica.

The press release contains forward-looking statements subject to risks and uncertainties that could affect actual results and outcomes for the companies involved. Investors are advised to use caution when relying on these forward-looking statements as they are valid only as of the release date and are subject to change as per legal requirements.

For further details and contacts, interested parties can reach out to Scilex Holding Company.

The full text of the press release is available for reference.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Vickers Vantage Corp. I’s 8K filing here.

About Vickers Vantage Corp. I

As of November 10, 2022, Vickers Vantage Corp. I was acquired by Scilex Holding Company, in a reverse merger transaction. Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities.